ZORBTIVE
LOE Approachingsomatropin recombinant
BLAINJECTIONINJECTABLE
Approved
Dec 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZORBTIVE is a recombinant human growth hormone (somatropin) administered by injection. It is indicated for patients with short bowel syndrome to enhance fluid and nutrient absorption. The drug works by stimulating anabolic processes and improving intestinal function in this rare, specialized patient population.
LOE Approaching
Product approaching loss of exclusivity with modest competitive pressure (30/100), indicating a mature specialty franchise with limited team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZORBTIVE roles are concentrated in niche specialty commercial and market access functions serving a small, defined patient base. Career progression opportunities are limited by the product's orphan/rare disease market and approaching LOE, making this a specialist role rather than a platform for broad company advancement.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.